Regulatory / Tax Litigation
Jubilant Pharmova Subsidiary Receives ₹107.89 Crore Income Tax Adjustment Order for FY23
NSE
JUBLPHARMA
BSE
530019
Jubilant Pharmova Limited informed exchanges that its wholly owned step-down subsidiary, Jubilant Generics Limited (JGL), received an Income Tax Department order involving FY23 tax adjustments of ₹107.89 crore, primarily linked to transfer pricing matters. The company plans to challenge the order before appellate authorities and stated that it does not expect any material financial impact.
PRICE-SENSITIVE TRIGGER
Event: Income Tax Department Order Received by Subsidiary
Type: Regulatory / Tax Litigation
Impact: Neutral
Immediate Effect: The company disclosed receipt of a tax adjustment order against subsidiary Jubilant Generics Limited, while simultaneously confirming plans to file an appeal and seek relief from appellate and advance pricing authorities.
Key Metrics:
- Tax Adjustment Amount:
- ₹107.89 crore
- Related to FY23 transfer pricing adjustments
- Deferred Tax Asset Impact:
- Reduction of ₹37.70 crore
- Material Financial Impact:
- Company stated no material financial implications expected
Highlight:
- Jubilant Generics Limited received a ₹107.89 crore tax adjustment order, but management believes the adjustments are contestable and expects relief through appellate proceedings.
What Happened ?
Jubilant Pharmova Limited informed stock exchanges that its wholly owned step-down subsidiary, Jubilant Generics Limited (JGL), received an order from the Income Tax Department dated May 21, 2026, with receipt confirmed on May 22, 2026 at 8:42 AM IST.
The order pertains to FY23 tax adjustments amounting to ₹107.89 crore, primarily arising from transfer pricing adjustments that, according to the company, ignored JGL’s submissions and contentions.
Management stated that:
- An appeal will be filed before the Commissioner of Income Tax (Appeals)
- A separate application before the Advance Pricing Authority has already been filed
- The company expects the disputed tax adjustments to be deleted after adjudication or redressal proceedings
The company further clarified that it does not foresee any material operational or financial disruption from the matter.
Key Details
Tax Litigation Details:
- Entity involved:
- Jubilant Generics Limited (JGL), wholly owned step-down subsidiary of Jubilant Pharmova
- Opposing authority:
- Income Tax Department
- Nature of dispute:
- FY23 transfer pricing tax adjustments
- Order amount:
- ₹107.89 crore
- Date of order:
- May 21, 2026
- Date and time of receipt:
- May 22, 2026 at 8:42 AM IST
- Legal action planned:
- Appeal before Commissioner of Income Tax (Appeals)
- Additional regulatory process:
- Application already filed before Advance Pricing Authority
- Accounting implication:
- Deferred tax asset reduction of ₹37.70 crore
Note:
- The company stated that the impugned adjustments were made ignoring facts and company contentions, and management expects favorable resolution through appellate proceedings.
Risk Analysis
Summary:
- The development introduces regulatory and tax litigation risk; however, management currently believes the exposure is manageable and unlikely to materially impact operations or financial stability.
Key Risks:
- Tax authorities have raised transfer pricing adjustments for FY23.
- The dispute may require prolonged litigation and appellate proceedings.
- Reduction in deferred tax assets of ₹37.70 crore could affect reported accounting metrics.
- Final outcome depends on appellate authority decisions and regulatory interpretation.
- Adverse ruling could increase tax liabilities and cash outflows.
Worst Case Scenario:
- If appellate authorities reject the company’s arguments, Jubilant Generics may face higher tax liabilities, additional penalties, and further deferred tax asset adjustments.
Risk Level: Medium
Company Commentary
- Jubilant Generics believes the tax adjustments were made ignoring the facts and contentions submitted by the company.
- Management confirmed that an appeal is being filed before the Commissioner of Income Tax (Appeals).
- The company has separately filed an application before the Advance Pricing Authority.
- Jubilant Pharmova stated that post adjudication and redressal processes, the disputed adjustments are likely to be deleted.
- The company does not anticipate any material financial implications from the order.
Official Exchange Filing: Jubilant Pharmova Limited